3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
3
Completed
2
Suspended
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
511
Uterine Cervical Neoplasms
361
Endometrial Neoplasms
305
Breast Neoplasms
129
Colorectal Neoplasms
114
Neoplasms
98
Fallopian Tube Neoplasms
91
Carcinoma, Non-Small-Cell Lung
87
Stomach Neoplasms
85
Pancreatic Neoplasms
80
Lung Neoplasms
73
Melanoma
68
Prostatic Neoplasms
67
Carcinoma, Ovarian Epithelial
65
Neoplasm Metastasis
63
Triple Negative Breast Neoplasms
51
Vulvar Neoplasms
49
Squamous Cell Carcinoma of Head and Neck
49
Head and Neck Neoplasms
45
Esophageal Neoplasms
45
Peritoneal Neoplasms
41
Uterine Neoplasms
40
Urinary Bladder Neoplasms
39
Carcinoma, Hepatocellular
35
Carcinoma, Renal Cell
34
Uterine Cervical Dysplasia
31
Papillomavirus Infections
31
Colonic Neoplasms
31
Sarcoma
30
Recurrence
29
Interventions
artesunic acid
1
artenimol
1
artemisinin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Vulvar Diseases
×
Gynecologic
×
Clear all
NCT06495554
2026-04-29
DaVulvaRec
University of Aarhus
Phase NA
Recruiting
1,295 enrolled
NCT06075264
2025-08-14
ART-VIN IIB
Frantz Viral Therapeutics, LLC
Phase 2
Recruiting
27 enrolled
NCT05592626
2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
365 enrolled